Gd-BOPTA: "the MRA contrast agent of choice"?

Abstract

Gd-BOPTA is a new positive MR contrast agent for intravenous application. In comparison to other gadolinium-chelates it has a nearly two-fold increased relaxivity due to weak protein binding with plasmatic macromolecules. In the papers published yet it has been evaluated to be useful for liver imaging. The purpose of this study was to evaluate, whether Gd-BOPTA is suited as an "magnetic resonance angiography (MRA) contrast agent". We examined four patients (aortic dissection, carotid artery stenosis, portal vein stenosis, exclusion of subclavian artery stenosis) with Gd-BOPTA with a dosage of 0.05 mmol/kg body weight. Furthermore, peripheral MRA of the pelvis and lower extremities was acquired in two healthy volunteers comparing 0.1 mmol Gd-DTPA/kg with 0.1 mmol Gd-BOPTA/kg. There was a delay of one week between the Gd-DTPA and the Gd-BOPTA examinations. In another volunteer Gd-BOPTA was reduced to 0.05 mmol/kg. The patient examinations revealed sufficient quality comparable with Gd-DTPA examinations despite of reduced dosage. In the volunteers Gd-BOPTA proved to be superior especially in the delineation of small pedal arteries which is important for surgical planning. These preliminary results demonstrate the potential of Gd-BOPTA to become a useful contrast agent for MRA. Its efficacy for this purpose has to be evaluated in future prospective studies.